Lymphocyte-suppressing action of angiotensin-converting enzyme inhibitors in coronary artery disease patients with normal blood pressure

Pharmacological Reports

Volumn 63, Issue 5, 2011, Pages 1151-1161

  Krysiak, Robert ^a   Okopień, Bogusław ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Angiotensin converting enzyme inhibitors; Coronary artery disease; Lymphocytes; Proinflammatory cytokines; Risk factors

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; GAMMA INTERFERON; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 2; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PERINDOPRIL; PLACEBO; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD PRESSURE MEASUREMENT; CELL FUNCTION; CONTROLLED STUDY; CORONARY ARTERY DISEASE; COUGHING; CYTOKINE RELEASE; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG MECHANISM; DRUG WITHDRAWAL; FEMALE; GLUCOSE METABOLISM; HUMAN; HYPOTENSION; INSULIN RESISTANCE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SENSITIVITY ANALYSIS; T LYMPHOCYTE ACTIVATION;

EID: 83155192335     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(11)70634-X     Document Type: Article

References (29)

1. Constantinescu CS, Goodman DB, Ventura ES: Captopril and lisinopril suppress production of interleukin-12 by human peripheral blood mononuclear cells. Immunol Lett, 1998, 62, 25-31. (Pubitemid 28277393)
2. Dagenais GR, Pogue J, Fox K, Simoons ML, Yusuf S: Angiotensin-converting- enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet, 2006, 368, 581-588. (Pubitemid 44209181)
3. Dendorfer A, Dominiak P, Schunkert H: ACE inhibitors and angiotensin II receptor antagonists. Handb Exp Pharmacol, 2005, 170, 407-442.
4. Fox KM; EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators: Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebocontrolled, multicentre trial (the EUROPA study). Lancet, 2003, 62, 782-788.
5. Fukuzawa M, Satoh J, Sagara M, Muto G, Muto Y, Nishimura S, Miyaguchi S et al.: Angiotensin converting enzyme inhibitors suppress production of tumor necrosis factor-alpha in vitro and in vivo. Immunopharmacology, 1997, 36, 49-55. (Pubitemid 27153477)
6. Garanty-Bogacka B, Syrenicz M, Syrenicz A, Gebala A, Lulka D, Walczak M: Serum markers of inflammation and endothelial activation in children with obesityrelated hypertension. Neuro Endocrinol Lett, 2005, 26, 242-246. (Pubitemid 40975104)
7. Hansson GK: Inflammatory mechanisms in atherosclerosis. J Thromb Haemost, 2009, 7, Suppl 1, 328-331.
8. Kinlay S, Egido J: Inflammatory biomarkers in stable atherosclerosis. Am J Cardiol, 2006, 98, 2P-8P.
9. Kothari SA, Le MK, Gandhi PJ: Effects of angiotensin converting enzyme inhibitors on thrombotic mediators: potential clinical implications. J Thromb Thrombolysis, 2003, 15, 217-225. (Pubitemid 38213192)
10. Krysiak R, Okopień B: Lymphocyte-suppressing effect of simvastatin in mixed dyslipidemic but not impaired glucose tolerance patients. Pharmacol Rep, 2011, 63, 95-101.
11. Krysiak R, Okopień B: Pleiotropic effects of angiotensin- converting enzyme inhibitors in normotensive patients with coronary artery disease. Pharmacol Rep, 2008, 60, 514-523.
12. Krysiak R, Okopień B: The effect of ezetimibe and simvastatin on monocyte cytokine release in patients with isolated hypercholesterolemia. J Cardiovasc Pharmacol, 2011, 57, 505-512.
13. Krysiak R, Sierant M, Marek B, Okopień B: The effect of angiotensin-converting enzyme inhibitors on plasma adipokine levels in normotensive patients with coronary artery disease. Pol J Endocrinol, 2010, 61, 280-287.
14. Krysiak R, Stachura-Kułach A, Okopień B: Metabolic and monocyte-suppressing actions of fenofibrate in patients with mixed dyslipidemia and early glucose metabolism disturbances. Pharmacol Rep, 2010, 62, 120-130.
15. Krysiak R, Żmuda W, Okopień B: The effect of ezetimibe, administered alone or in combination with simvastatin, on lymphocyte cytokine release in patients with elevated cholesterol levels J Intern Med, 2011, doi: 10.1111/j.1472-8206.2011.00932.x.
16. Madej A, Okopień B, Kowalski J, Haberka M, Herman ZS: Plasma concentrations of adhesion molecules and chemokines in patients with essential hypertension. Pharmacol Rep, 2005, 57, 878-881.
17. Naftilan AJ: Role of the tissue renin-angiotensin system in vascular remodeling and smooth muscle cell growth. Curr Opin Nephrol Hypertens, 1994, 3, 218-227.
18. Neultel JM: Effect of the renin-angiotensin system on the vessel wall: using ACE inhibition to improve endothelial function. J Hum Hypertens, 2004, 18, 599-606.
19. Okopień B, Krysiak R, Kowalski J, Madej A, Belowski D, Zieliński M, Łabuzek K et al.: The effect of statins and fibrates on interferon-gamma and interleukin-2 release in patients with primary type II dyslipidemia. Atherosclerosis, 2004, 176, 327-335. (Pubitemid 39369523)
20. PROGRESS Collaborative Group: Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet, 2001, 358, 1033-1041.
21. Ridker PM: Inflammatory biomarkers and risks of myocardial infarction, stroke, diabetes, and total mortality: implications for longevity. Nutr Rev, 2007, 65, S253-259.
22. Schindler R, Dinarello CA, Koch KM: Angiotensinconverting- enzyme inhibitors suppress synthesis of tumour necrosis factor and interleukin 1 by human peripheral blood mononuclear cells. Cytokine, 1995, 7, 526-533.
23. Schroecksnadel K, Frick B, Winkler C, Fuchs D: Crucial role of interferon-gamma and stimulated macrophages in cardiovascular disease. Curr Vasc Pharmacol, 2006, 4, 205-213. (Pubitemid 46785488)
24. Sironi L, Nobili E, Gianella A, Gelosa P, Tremoli E: Anti-inflammatory properties of drugs acting on the renin-angiotensin system. Drugs Today, 2005, 41, 609-622. (Pubitemid 41810476)
25. Śliż D, Mamcarz A, Filipiak KJ, Siebert J, Naruszewicz M: 3ST-POL trial: standards of statin use in Poland in the context of the European Society of Cardiology guidelines. Pol Arch Med Wewn, 2010, 120, 328-333.
26. Tedgui A, Mallat Z: Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev, 2006, 86, 515-581.
27. The PEACE Trial Investigators: Angiotensin-convertingenzyme inhibition in stable coronary artery disease. N Engl J Med, 2004, 351, 2058-2068.
28. Weyand CM, Younge BR, Goronzy JJ: T cells in arteritis and atherosclerosis. Curr Opin Lipidol, 2008, 19, 469-477.
29. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med, 2000, 342, 145-153.